Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
- Conditions
- Recurrent High Grade Gliomas
- Interventions
- Device: 3T MRI
- Registration Number
- NCT00942760
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Brief Summary
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a tissue sample. The hypotheses of the study is to determine if multimodal MR technique will provide tissue signatures that differentiate between tumor progression and treatment related necrosis in high grade glioma patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Histologically proven high grae glioma with central pathology review at DHMC
- Age 18 equal to or greater than 18 years
- Karnofsky performance greater or equal to 60%
- Patients must have received radiation therapy and chemotherapy but should not have received any anti-angiogenesis therapy.
- Any patient who requires urgent surgical resection of MRI abnormality would not be eligible
- Pregnant women are not eligible
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Research MRI 3T MRI High Grade Glioma patients who show progression based on MRI
- Primary Outcome Measures
Name Time Method To prospectively acquire multiparameter MR variables at 1.5T and 3T MRI from treated high grade glioma patients to assign tissue signatures for tumor recurrence and radiation necrosis as established by pathologic examination. 24 months
- Secondary Outcome Measures
Name Time Method To compare the predictive values of the multiparameter MR tissue signatures acquired at 1.5T and 3T 24 months
Trial Locations
- Locations (1)
Dartmouth-Hitchcock Medical Center
πΊπΈLebanon, New Hampshire, United States